Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

ADC Therapeutics (ADCT) Gains from Sales and Divestitures: 2019-2022

Historic Gains from Sales and Divestitures for ADC Therapeutics (ADCT) over the last 3 years, with Dec 2022 value amounting to $553.

  • ADC Therapeutics' Gains from Sales and Divestitures fell 12.72% to $3.4 million in Q3 2023 from the same period last year, while for Sep 2023 it was $3.4 million, marking a year-over-year decrease of 12.72%. This contributed to the annual value of $553 for FY2022, which is 4.14% up from last year.
  • As of FY2022, ADC Therapeutics' Gains from Sales and Divestitures stood at $553, which was up 4.14% from $531 recorded in FY2021.
  • ADC Therapeutics' Gains from Sales and Divestitures' 5-year high stood at $553 during FY2022, with a 5-year trough of $329 in FY2019.
  • Over the past 2 years, ADC Therapeutics' median Gains from Sales and Divestitures value was $542 (recorded in 2021), while the average stood at $542.
  • Data for ADC Therapeutics' Gains from Sales and Divestitures shows a peak YoY climbed of 4.14% (in 2022) over the last 5 years.
  • Yearly analysis of 3 years shows ADC Therapeutics' Gains from Sales and Divestitures stood at $329 in 2019, then reached $531 in 2021, then rose by 4.14% to $553 in 2022.